The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 2, 2001, Pages 275-280

  Zuberbier, Torsten ^a   Chong, Sie Uen ^a   Grunow, Karl ^a   Guhl, Sven ^a   Welker, Pia ^a   Henz, Beate M ^a   Grassberger, Maximilian ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Novartis Forschungs Institut   (Australia)

Author keywords

Allergy; Ascomycin; Histamine, SDZ ASM 981; Macrophilin; Mast cell; Pimecrolimus

Indexed keywords

CALCIMYCIN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE C4; PHORBOL 13 ACETATE 12 MYRISTATE; PIMECROLIMUS; RAPAMYCIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BASOPHIL; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG INDICATION; DRUG MECHANISM; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MAST CELL; PRIORITY JOURNAL;

EID: 0034909508     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.116865     Document Type: Article

References (32)

1. Anti-inflammatory effect of cyclosporin A on human skin mast cells
2. Anti-inflammatory effect of FK-506 on human skin mast cells
3. Ascomycins: Promising agents for the treatment of inflammatory skin diseases
4. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
5. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
6. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
7. Atopic dermatitis-like symptoms in hypomagnesemic hairless rats are prevented and inhibited by sytemic or topical SDZ ASM 981
8. SDZ ASM 981: Mode of action and pharmacological selectivity
9. Ascomycins in dermatology
10. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis
11. Human mast cell heterogeneity: Histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli
12. Monoclonal antibody YB5 B8 identifies the human c-kit protein product
13. Refinements in the automated fluorometric histamine analysis system
14. Human skin tryptase: Purification, partial characterization and comparison with human lung tryptase
15. Chemistry and biology of the immunophilins and their immunosuppressive ligands
16. Probing immunosuppressant action with a nonnatural immunophilin ligand
17. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
18. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription
19. Mast cells
20. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: Tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells
21. Potent induction of a neutrophil and eosinophilrich infiltrate in vivo by human mast cell tryptase: Selective enhancement of eosinophil recruitment by histamine
22. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase
23. Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi
24. Elevated soluble tumor necrosis factor receptor levels in seasonal allergic rhinitis patients
25. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75, in atopic children
26. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis
27. Upregulation of tumor necrosis factor α and interleukin-3 expression in lesional and uninvolved skin in different types of urticaria
28. Pathophysiology of the inflammatory response
29. Mast cells enhance eosinophil survival in vitro: Role of TNT-alpha and granulocyte-macrophage colony-stimulating factor
30. Human synovial mast cells, II. Heterogeneity of the pharmalogical effects of antiinflammatory and immunosuppressive drugs
31. SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis